Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 158.03 [7][8]. Core Views - The company has returned to growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items showing year-on-year increases of 5.4%, 1.9%, and 26.1% respectively [1]. - The company is expected to achieve steady growth in 2025, driven by improved domestic equipment update policies and ongoing global expansion efforts [1]. Revenue and Profitability - For 2024, the company reported revenues of RMB 103.00 billion, a year-on-year decline of 9.7%, with net profit attributable to the parent at RMB 12.62 billion, down 36.1% [1]. - In Q1 2025, the company achieved revenues of RMB 24.78 billion, with a gross margin of 49.9%, reflecting a 0.4 percentage point increase year-on-year [1]. Business Segments - Equipment Products: In 2024, revenue from equipment products was RMB 84.45 billion, down 14.9% year-on-year, but the RT business saw a revenue increase of 18.1% [2]. - Maintenance Services: Revenue from maintenance services in 2024 was RMB 13.56 billion, up 26.8% year-on-year, with a gross margin of 63.4% [2]. Market Performance - Domestic Market: In 2024, domestic revenue was RMB 80.34 billion, down 17.5% year-on-year, but the company maintained the highest market share in new imaging products [3]. - International Market: In 2024, international revenue reached RMB 22.66 billion, up 35.1% year-on-year, with operations in over 85 countries [3]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025 is RMB 2.43, with a projected PE ratio of 65x for 2025 [4]. - The target price of RMB 158.03 corresponds to a 54x PE for 2025, compared to a comparable company average PE of 45x [4].

Investment Rating - The report rates the pharmaceutical industry as "Overweight" [1] Core Insights - The total market capitalization of pharmaceutical stocks in public offering funds increased from RMB 233.40 billion to RMB 238.30 billion, reflecting a growth of 2% [30][31] - The proportion of pharmaceutical stocks in all fund holdings slightly increased to 7.87%, up by 0.36 percentage points from the previous quarter [31] - The report expresses optimism about the growth potential of the pharmaceutical industry, driven by continuous technological innovation and demand [30] Summary by Sections 1. Fund Holdings Ratio - The proportion of pharmaceutical stocks in public funds saw a slight recovery, with a total market cap increase from RMB 233.40 billion to RMB 238.30 billion [6][30] - As of Q1 2025, pharmaceutical stocks accounted for 7.87% of all public offering fund long positions, an increase of 0.36 percentage points from Q4 2024 [31] 2. Sector Analysis - The leading sectors in public fund holdings of pharmaceutical stocks in Q1 2025 were: 1) Chemical preparations: RMB 85.20 billion, 36% 2) Medical devices: RMB 44.70 billion, 19% 3) Medical R&D outsourcing: RMB 44.50 billion, 19% [32][10] 3. Top Holdings - The top five public offering fund long positions by market capitalization in Q1 2025 were: 1) Jiangsu Heng Rui Medicine: RMB 32.30 billion 2) WuXi AppTec: RMB 27.60 billion 3) Mindray Medical: RMB 25.60 billion 4) United Imaging: RMB 9.80 billion 5) BeiGene: RMB 9.00 billion [33][20] - The top five growth in public offering fund long positions by market capitalization were: 1) WuXi AppTec: +RMB 6.20 billion 2) BeiGene: +RMB 4.40 billion 3) Sichuan Kelun Pharmaceutical: +RMB 2.60 billion 4) Jiangsu Heng Rui Medicine: +RMB 2.40 billion 5) Pharmaron: +RMB 0.90 billion [25][33]

Core Viewpoint - Wangsu Technology and United Imaging Medical Technology have signed a cooperation agreement to establish an AI medical-focused computing center, aiming to enhance the digital transformation of the healthcare sector [1] Group 1: Partnership Details - The partnership will leverage Wangsu's Shanghai Jiading Cloud Computing Data Industrial Park to build a computing cluster that supports United Imaging's comprehensive digital transformation across R&D, supply chain, marketing, and services [1] - The initiative aims to boost technological innovation and productivity, facilitating the domestic replacement process of medical devices [1] Group 2: Project Objectives - The project will support the establishment and operation of United Imaging's enterprise-level large model platform and the development of intelligent applications [1] - By fostering open innovation capabilities, the partnership seeks to drive digital transformation across the upstream and downstream of the medical industry, enhancing the quality and efficiency of the industrial chain [1]

Core Viewpoint - The digital subtraction angiography system (DSA) uAngioAVIVA developed by United Imaging Healthcare has received FDA approval on April 28, making it the first and only domestic DSA device authorized for the U.S. market [1] Company Summary - United Imaging Healthcare has successfully developed a DSA system that meets FDA standards, indicating a significant achievement in the medical device sector [1] - The approval opens up new market opportunities for the company in the U.S., potentially increasing its market share and revenue [1] Industry Summary - The approval of a domestic DSA device highlights the growing capabilities of Chinese medical technology firms in competing in international markets [1] - This event may signal a shift in the competitive landscape of the medical imaging industry, as domestic products gain regulatory acceptance in major markets like the U.S. [1]

Group 1 - The core viewpoint emphasizes the role of finance in supporting national strategies, poverty alleviation, and technological independence, showcasing the commitment of professionals like Wu Bin in the financial sector [1][2] - Wu Bin has been instrumental in facilitating significant IPOs, such as Huahong Semiconductor, and breaking foreign monopolies in medical imaging by assisting United Imaging Healthcare in its listing on the Sci-Tech Innovation Board [1] - The introduction of the first domestic green securities and the promotion of green finance initiatives across multiple regions, including airports and rail transit, highlights the push towards sustainable development [1] Group 2 - Wu Bin's leadership in the 13.8 billion yuan CMBS project demonstrates the ability to bridge financial capital with the real economy, ensuring successful project execution [2] - The establishment of youth service points for state-owned enterprises under Wu Bin's guidance fosters resource sharing and collaboration among young professionals, encouraging their involvement in innovative industries [2] - Wu Bin's approach to finance emphasizes practical action and community engagement, reinforcing the idea that finance serves the people through tangible efforts in various sectors [2]

Core Insights - The company experienced a decline in its main detector business due to weak industry demand, but new products showed significant growth [1] - The overall gross margin decreased, coupled with increased management and financial expenses, leading to a drop in net profit margin [2] - The company is optimistic about a turnaround in performance for the full year 2025, supported by improved market conditions and contract liabilities growth [3] - The company is pursuing vertical integration and horizontal expansion to establish itself as a comprehensive component supplier [4] - The company plans to raise funds through a private placement to support the construction of X-ray vacuum devices and comprehensive solutions, which will enhance production capacity [5] Financial Performance - In 2024, the company achieved total revenue of 1.831 billion yuan, a year-on-year decrease of 1.74%, with the detector business revenue at 1.490 billion yuan, down 11.99% [1] - The overall gross margin for 2024 was approximately 50.11%, a decline of 7.73 percentage points year-on-year, with the detector gross margin at 56.65%, down 3.48 percentage points [2] - The net profit for 2024 was 465 million yuan, a year-on-year decline of 23.43%, resulting in a net profit margin of 25.40%, down 7.19 percentage points [2] Business Development - The company is actively developing upstream components and materials for detectors, with successful R&D and production of 2D collimators for medical CT and security CT applications [4] - The company has completed the R&D and initial production of high-voltage generators and combination ray sources, with plans for further expansion into more application areas [4] - The company aims to increase production capacity by 77,000 tubes and 19,300 sets of X-ray comprehensive solutions through a planned investment project [5] Future Outlook - The company expects revenue growth to reach 2.208 billion yuan in 2025, with net profit projected at 648 million yuan, indicating a potential performance reversal [5] - The company maintains a positive long-term growth outlook, supported by ongoing market recovery and expansion initiatives [5]

Group 1 - The CSI 300 Index experienced a slight decline of 0.02% as of April 29, 2025, with mixed performance among constituent stocks, led by Huichuan Technology with a rise of 4.41% [1] - The CSI 300 ETF saw significant growth in scale, increasing by 8.184 billion yuan over the past six months, and its shares grew by 4.032 billion [3] - The CSI 300 Index is currently valued at a historical low, with a price-to-book ratio (PB) of 1.34, which is below 80.83% of its historical data, indicating strong valuation attractiveness [3] Group 2 - The top ten weighted stocks in the CSI 300 Index as of March 31, 2025, include Kweichow Moutai, CATL, Ping An Insurance, and others, collectively accounting for 23.04% of the index [4] - Investors without stock accounts can access core A-share assets through the CSI 300 ETF linked fund, providing an opportunity for low-cost entry into the market [4]

Market Performance - The CSI Hong Kong Stock Connect Healthcare Index (930965) increased by 1.66% as of April 29, 2025, with notable gains from WuXi AppTec (02359) up 5.07%, and 3SBio (01530) up 4.41% [1] - The Hong Kong Healthcare ETF (159718) rose by 1.84%, closing at 0.72 yuan, with a weekly increase of 4.28% as of April 28, 2025 [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) saw a rise of 0.51%, with significant increases from companies like Xingqi Eye Hospital (300573) up 9.55% and WuXi AppTec (603259) up 3.80% [4][10] Liquidity and Scale - The Hong Kong Healthcare ETF had a turnover rate of 4.77% with a transaction volume of 12.78 million yuan, averaging daily transactions of 152 million yuan over the past week [1] - The Medical Innovation ETF had a turnover rate of 0.23% with a transaction volume of 3.81 million yuan, averaging daily transactions of 52.36 million yuan over the past month [5] Investment Trends - The upcoming ASCO conference from May 30 to June 3, 2025, is expected to showcase over 70 oral presentations and 10 significant studies from domestic innovative drug companies [2] - According to Guotou Securities, global and U.S. VC & PE investment in innovative drugs is projected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the investment environment for innovative drugs [2] - Demand for research and development in areas such as peptides and ADCs is increasing, leading to improved order conditions for CXO listed companies like WuXi AppTec and others [2] Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Healthcare Index account for 59.76%, with WuXi Biologics (02269) holding the highest weight at 11.32% [7][9] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represent 66.49%, with WuXi AppTec (603259) at 11.68% [10][12]

Core Viewpoint - The concept of "domestic substitution" is evolving from a perception of being a second-best option to a strategic necessity, reflecting advancements in Chinese technology and manufacturing capabilities [1][2]. Group 1: Domestic Substitution and Technological Advancements - Domestic substitution is not merely about replacing imported components but involves a comprehensive restructuring of the industrial chain, technology standards, and market rules [2]. - In the medical device sector, companies like United Imaging Healthcare have launched innovative products that have entered the global high-end market, showcasing that domestic products are not inferior but competitive [1]. - The Chinese electric vehicle industry has established a complete ecosystem from lithium mining to vehicle manufacturing, pushing global automotive standards towards "Chinese standards" [2]. Group 2: Impact of External Pressures - The U.S. technology blockade has inadvertently accelerated the pace of domestic substitution, compelling Chinese companies to innovate and compete globally [2]. - DeepSeek, a representative AI company in China, has emerged as a competitor to OpenAI, demonstrating that external pressures can catalyze technological innovation [2]. - Following supply chain disruptions, Huawei's HarmonyOS has been installed on over 1 billion devices, indicating significant progress in domestic technology [2]. Group 3: Challenges and Opportunities - Despite challenges such as weak foundational research and a shortage of high-end talent, the environment for innovation in China is improving [3]. - In 2024, China's total R&D expenditure is projected to reach 36,130 billion yuan, an 8.3% increase from the previous year, maintaining its position as the second-largest R&D investor globally [3]. - Over 570 Chinese industrial companies are among the global top 2,500 in R&D investment, highlighting the growing strength of domestic innovation [3].

Core Viewpoint - The company has released its 2024 ESG report, highlighting its initiatives and achievements in environmental, social, and governance areas, with a strong focus on green and low-carbon development [1] Group 1: Environmental Initiatives - The company has established a cross-departmental carbon management team and set clear greenhouse gas reduction targets, aiming to reduce Scope 1 and Scope 2 carbon emission intensity by 50% by 2035, using 2023 as the baseline [1] - In 2024, the company's greenhouse gas emissions amounted to 54,443.92 tons CO2e (Scope 1 and Scope 2, based on market), representing a 28% reduction (21,000 tons CO2e) compared to the 2023 baseline [1] - The greenhouse gas emission intensity decreased to 5.29 tons CO2e per million revenue, a year-on-year decline of 21%, with 41% of the mid-term goal of a 50% reduction by 2035 already achieved [1] Group 2: Technological Advancements - The company has launched the world's first silicon carbide MRI, which improves intelligent diagnostic efficiency by 30% and reduces equipment energy consumption by 57% [2] - The new generation PET/CT product utilizes more environmentally friendly materials and technologies to replace traditional lead shielding structures, effectively reducing environmental pollution [2] - The breast DR limiter innovatively uses steel instead of lead for X-ray limiting and shielding, achieving environmentally friendly and harmless solutions [2] - In the transportation segment, the company employs cold chain transportation technology for MRI equipment, significantly reducing liquid helium consumption, saving nearly 700,000 liters in 2024 [2]